Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) officially listed on the Hong Kong Stock Exchange, attracting significant investor interest due to its solid technology and clear pipeline in the biotech sector [1] Company Overview - Ribo Bio's global offering consisted of 31.61 million shares at an issue price of HKD 57.97 per share, with the first-day opening price at HKD 75, reflecting a 29.38% increase from the issue price [1] - The public offering was oversubscribed over 100 times, and the international offering was 16.7 times oversubscribed, raising over HKD 1.8 billion [1] - The company is recognized as a key player in the small nucleic acid technology and pharmaceutical field in China, attracting participation from notable domestic and international investment institutions [1] Technology and Product Pipeline - Ribo Bio possesses a clinically validated liver-targeting GalNAc delivery technology, RiboGalSTAR™, which enables efficient and specific delivery of siRNA to liver cells [2] - The company has established a robust product pipeline with seven self-developed siRNA candidates in clinical stages, including RBD4059, the first siRNA drug targeting FXI for thrombotic diseases [2][3] - RBD4059 shows potential advantages in reducing bleeding risk while effectively combating thrombosis, with a long-acting profile that may extend dosing intervals to several months [2] Market Potential - The global small nucleic acid drug market is experiencing rapid growth, projected to increase from USD 2.7 billion in 2019 to USD 5.7 billion in 2024, and expected to reach USD 20.6 billion and USD 54.9 billion by 2029 and 2034, respectively [3] - Ribo Bio's pipeline aligns with significant unmet clinical needs, particularly in thrombotic diseases and hypertriglyceridemia, which are prevalent and have substantial patient populations [4] - RBD4059 and RBD5044 are positioned to address limitations of current therapies, with RBD5044 targeting high triglyceride levels showing potential to become a best-in-class therapy [4] Future Outlook - The successful listing on the Hong Kong Stock Exchange marks a new chapter for Ribo Bio, providing capital to support its development [5] - With a solid research foundation, differentiated product pipeline, and clear commercial strategy, Ribo Bio is poised to become an influential player in the global small nucleic acid therapy landscape, offering new treatment hopes for millions of patients worldwide [5]

Group 1 - Suzhou Rebio Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange on January 9, becoming the first listed company in Jiangsu province this year [1] - The company issued 31.61 million shares at a price of HKD 57.97 per share, raising over HKD 1.8 billion in total [1] - Rebio, founded in 2007 and headquartered in Suzhou, focuses on the research and development of small nucleic acid drugs, utilizing RNA interference (RNAi) technology to develop innovative therapies for major diseases [1] Group 2 - Rebio's research pipeline covers various diseases, particularly chronic diseases, with seven self-developed drugs currently in clinical trials, four of which are in Phase II [1] - The core product, RBD4059, is the world's first clinical-stage small nucleic acid drug for treating thrombotic diseases, offering significant advantages over traditional treatments, such as extended efficacy and lower bleeding risks [1] - With Rebio's listing, the number of companies listed from Suzhou on the Hong Kong Stock Exchange has increased to 42, further expanding the biopharmaceutical sector in the region [2]

Core Insights - Alnylam's growth path is mirrored by China's small nucleic acid drug pioneer, Rebio Biotech, which recently went public in Hong Kong, raising over HKD 1.8 billion with a strong demand from investors [1] - The global small nucleic acid drug market is projected to grow from USD 2.7 billion in 2019 to USD 5.7 billion by 2024, with a compound annual growth rate (CAGR) of 16.2% [2] - Rebio Biotech has established a robust technology platform, particularly in delivery systems, which is crucial for the efficacy and safety of siRNA therapies [3][4] Company Overview - Rebio Biotech is recognized as a leader in China's small nucleic acid field, often referred to as the "Chinese version of Alnylam," due to its comprehensive technology platform and rapid pipeline development [1] - The company has developed a proprietary GalNAc delivery technology that enhances the therapeutic efficacy of siRNA drugs, addressing a significant challenge in the industry [3] - Rebio's RiboGalSTAR platform is the first and only RNAi technology platform developed in China that has been licensed to a global multinational company [3] Research and Development - The company has invested significantly in R&D, with expenditures of CNY 315 million, CNY 280 million, and CNY 135 million planned for 2023, 2024, and the first half of 2025, respectively, totaling CNY 730 million over two and a half years [4] - Rebio Biotech's R&D efforts have led to a comprehensive technology platform that covers the entire drug development cycle, from design to production [4] Product Pipeline - Rebio Biotech has created one of the largest siRNA drug pipelines globally, with seven self-developed drug assets currently in clinical trials targeting various diseases, including cardiovascular and metabolic disorders [5] - The core product, RBD4059, is the world's first siRNA drug for treating thrombotic diseases and is progressing rapidly through clinical development [7] - The company also has two additional drugs targeting hypertriglyceridemia and hypercholesterolemia, which could provide synergistic effects in managing lipid disorders [8] Market Potential - The company anticipates significant revenue growth, projecting revenues of CNY 143 million in 2024 and CNY 103 million in the first half of 2025, representing a year-on-year increase of 56.57% [9] - As Rebio's main product pipelines approach commercialization, the company's growth potential is expected to be realized, leading to a quicker path to profitability [9] Conclusion - Rebio Biotech's journey reflects the potential of small nucleic acid drugs, with a strong foundation in technology and a diverse pipeline [10] - The recent IPO marks a critical step for Rebio Biotech in becoming a leading player in the global small nucleic acid drug market, with the backing of capital markets to accelerate its growth [10]

Core Insights - Alnylam's growth path is mirrored by China's small nucleic acid drug pioneer, Rebio Biotech, which recently went public on the Hong Kong Stock Exchange, raising over HKD 1.8 billion with a strong demand from investors [1][11] - The global small nucleic acid drug market is projected to grow from USD 2.7 billion in 2019 to USD 5.7 billion by 2024, with a compound annual growth rate (CAGR) of 16.2%, and expected to reach USD 20.6 billion and USD 54.9 billion by 2029 and 2034, respectively [2] - Rebio Biotech has established a robust technical platform and delivery system, addressing key challenges in the industry and creating a strong competitive moat [3][4] Company Overview - Rebio Biotech is recognized as a leader in China's small nucleic acid field, with a comprehensive technology platform and a rapidly advancing pipeline [1][11] - The company has developed the RiboGalSTAR™ delivery technology, which enhances the efficacy and safety of siRNA drugs, addressing a critical challenge in the industry [3][4] - The company has invested significantly in R&D, with expenditures of CNY 315 million, CNY 280 million, and CNY 135 million projected for 2023, 2024, and the first half of 2025, respectively [4] Pipeline and Product Development - Rebio Biotech has created one of the largest siRNA drug pipelines globally, with seven self-developed drug assets in clinical trials targeting various diseases [5][7] - The core product, RBD4059, is the world's first siRNA drug for treating thrombotic diseases, currently advancing rapidly through clinical development [7][8] - The company also has two additional drugs targeting hypertriglyceridemia and hypercholesterolemia, which could provide synergistic effects in lipid management [8] Market Potential and Financial Outlook - The company is expected to achieve revenue of CNY 143 million in 2024, with a projected growth to CNY 103 million in the first half of 2025, reflecting a year-on-year increase of 56.57% [9] - As the core pipeline progresses towards commercialization, Rebio Biotech's growth potential is anticipated to be realized, leading to a path towards profitability [10][11]

Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion through the issuance of 31.6104 million shares, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is a biopharmaceutical company focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, which targets FXI for the treatment of thrombotic diseases [1] - Rebio's pipeline includes seven self-developed drug assets currently in clinical trials, addressing cardiovascular, metabolic, renal, and liver diseases, with four of these in Phase 2 clinical trials [1] Clinical Development - In addition to the core product RBD4059, the company is advancing other clinical-stage products, including RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is also a differentiated siRNA candidate for coronary heart disease (CHD) [1] - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]

Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, aimed at treating thrombotic diseases, and has a pipeline of seven self-developed drug assets currently in clinical trials [1] Clinical Pipeline - The clinical pipeline includes treatments for cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1] - In addition to RBD4059, the company is advancing other clinical-stage products such as RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is a differentiated siRNA candidate for coronary heart disease (CHD) [1] Preclinical Projects - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]

Group 1 - The core viewpoint of the article is that Rebio Pharmaceuticals-B (6938.HK) is set to be listed on the Hong Kong Stock Exchange tomorrow, with significant interest shown in pre-listing trading [1] - In dark pool trading today, the stock price surged nearly 40%, reaching HKD 81, indicating strong market demand [1] - Each trading lot consists of 200 shares, allowing investors to potentially earn HKD 4,606 per lot, highlighting the lucrative opportunity for early investors [1] Group 2 - Rebio Pharmaceuticals specializes in the research and development of small nucleic acid drugs, particularly focusing on siRNA therapies, positioning itself as a pioneer in this field since its inception in 2007 [1]

潛在投資者應注意，在穩定價格期間（自上市日期開始，預期於2026年2月5日（星期四）（即遞 交香港公開發售申請的截止日期後第30日）屆滿）之後，不得再採取穩定價格行動以支持H股價 格。在該日期後，將不再採取進一步穩定價格行動，屆時對H股的需求以及H股的價格可能會 下跌。 若在上市日期上午八時正前發生特定事件，整體協調人（為其本身及代表承銷商）可終止香港承 銷商在香港承銷協議項下認購及促使認購人認購香港發售股份的義務。相關理由載於招股章程 「承銷」一節。務請 閣下參閱該章節以了解進一步詳情。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛在 投資者在決定是否投資所發售的H股前，應閱覽蘇州瑞博生物技術股份有限公司（「本公司」）於 2025年12月31日刊發的招股章程（「招股章程」），以了解下述全球發售的詳盡資料。本公司並未 且將不會根據經修訂的《1940年美國投資公司法》進行登記。 除本公告另行界定外，本公告所用詞彙與招股章程所界定者具有相同涵義。 就全球發售而言，中國國際金融香港證券有限公司作為穩定價格操作人（「穩定價格操作人」） （或其聯屬人士或任何代其行事的人士）代表承銷商 ...

Suzhou Ribo Life Science Co., Ltd. 蘇州瑞博生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6938） 董事名單與其角色及職能 1 四個董事委員會各自的組成情況載列於下表： | 董事委員會 | | 薪酬與 | | | | --- | --- | --- | --- | --- | | 董事 | 審計委員會 | 考核委員會 | 提名委員會 | 戰略委員會 | | 梁子才博士 | | 成員 | | 主席 | | 甘黎明博士 | | | | 成員 | | 張鴻雁博士 | | | 成員 | | | 戚飛博士 | | | | 成員 | | 李東方先生 | | | | 成員 | | 李宇輝先生 | | | | 成員 | | 宇學峰博士 | 成員 | 成員 | 主席 | | | 馬朝松先生 | 主席 | | 成員 | | | 王瑞平先生 | 成員 | 主席 | | 成員 | 香港，2026年1月8日 蘇州瑞博生物技術股份有限公司董事（「董事」）會（「董事會」）成員載列如下： 梁子才博士 （董事長、執行董事兼首席執行官） 甘黎明博士 （執行董事） 張鴻雁博士 （ ...

蘇州瑞博生物技術股份有限公司 董事會戰略委員會實施細則 第一章 總則 第一條 為適應蘇州瑞博生物技術股份有限公司（以下簡稱「公司」或「本公 司」）戰略發展需要，增強公司核心競爭力，確定公司發展規劃，健全投資決策程 序，加強決策科學性，提高重大投資決策的效益和決策的質量，完善公司治理結 構，根據《中華人民共和國公司法》《香港聯合交易所有限公司證券上市規則》等 法律、法規、規範性文件以及《蘇州瑞博生物技術股份有限公司章程》（以下簡稱 「《公司章程》」）的有關規定，公司特設立董事會戰略委員會，並制訂本實施細則。 第二條 董事會戰略委員會是董事會按照股東會決議設立的專門工作機構， 主要負責對公司長期發展戰略和重大投資決策進行研究並提出建議。 第二章 人員組成 第三條 戰略委員會成員由三至七名董事組成，其中應至少包括一名獨立非 執行董事。 第四條 戰略委員會委員由董事長、二分之一以上獨立非執行董事或者全體 董事的三分之一以上提名，並由董事會選舉產生。 第五條 戰略委員會設主任委員（召集人）一名，由公司董事長擔任。 第六條 戰略委員會任期與董事會任期一致，委員任期屆滿，連選可以連 任。期間如有委員不再擔任公司董事職務，自 ...